Beactica Therapeutics AB, a Swedish precision medicine company, today announced that it, together with leading glioblastoma researchers at KU Leuven, has been awarded a EUR 2.5 million grant by the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results